Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626340 · ClinicalTrials.gov registry record · Phase 4
Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
A Phase 4 study of Depression and Menopause, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00626340: Completed Phase 4 study of Depression and Menopause, sponsored by University of Pennsylvania.
NCT00626340 is a Phase 4 study of Depression and Menopause that has completed, run by University of Pennsylvania. The registered enrollment target is 18 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00626340, a Phase 4 study of Depression and Menopause, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose this study is to measure cortical gama-aminobutyric acid levels (GABA) levels in menopausal women with major depressive disorder and healthy subjects using nuclear magnetic resonance spectroscopy (MRS). Measurements will be compared in 1) menopausal healthy subjects before and after estrogen replacement, and after fourteen days of medroxyprogesterone administration; and 2) in depressed menopausal subjects before and after treatment of their depression with antidepressant alone, estrogen alone or antidepressant plus estrogen. Cortical GABA levels will be correlated with plasma GABA and neurosteroid levels. Neurosteroids to be measured include progesterone, allopregnanolone, pregnenolone, and pregnenolone sulfate.
Primary Outcome
This study was conducted at Yale University almost two decades ago. Our group at the University of Pennsylvania only has very basic information about this study. This includes the number of participants, which was 18, and the fact that no adverse events occurred. Staff members at the University of Pennsylvania do not have access to any additional study data. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania and we are unable t
Conditions Studied
Interventions
- DRUG MDD diagnosis and Estrogen treatment
- DRUG MDD diagnosis and Fluoxetine treatment
- DRUG MDD diagnosis with both Estrogen and Fluoxetine treatment
- DRUG No depression and estrogen treatment
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1999-07 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
What the finished NCT00626340 record still lists
NCT00626340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 4 interventions - of which MDD diagnosis and Estrogen treatment is the first listed.
NCT00626340 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00626340 about?
NCT00626340 is a clinical study titled "Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder". The purpose this study is to measure cortical gama-aminobutyric acid levels (GABA) levels in menopausal women with major depressive disorder and healthy subjects using nuclear magnetic resonance spectroscopy (MRS). Measurements will be compared in 1) menopausal healthy subjects before and after estr...
What is the current status of trial NCT00626340?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 1999-07. Estimated completion is 2008-07.
What conditions does trial NCT00626340 study?
This clinical trial studies the following conditions: Depression, Menopause.
What interventions are being tested in trial NCT00626340?
The interventions under investigation include: MDD diagnosis and Estrogen treatment (DRUG), MDD diagnosis and Fluoxetine treatment (DRUG), MDD diagnosis with both Estrogen and Fluoxetine treatment (DRUG), No depression and estrogen treatment (DRUG).
Who is sponsoring clinical trial NCT00626340?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626340 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00626340's enrollment target sits among peer trials
18 626th of 679 higher than 50 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia